Constructing a Conceptual Framework of Patient-Reported Outcomes for Metastatic Hormone-Refractory Prostate Cancer

Author： Eton David T.   Shevrin Daniel H.   Beaumont Jennifer   Victorson David   Cella David  

Publisher： Blackwell Publishing

ISSN： 1098-3015

Source： Value in Health, Vol.13, Iss.5, 2010-08, pp. : 613-623

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Docetaxel: In Hormone-Refractory Metastatic Prostate Cancer

By McKeage Kate   Keam Susan J.  

Drugs, Vol. 65, Iss. 16, 2005-01 ,pp. : 2287-2294

Adis International

Access to resources Recommend Favorite

Docetaxel in Hormone-Refractory Metastatic Prostate Cancer: A Viewpoint by William R. Berry

By Berry William R.  

Drugs, Vol. 65, Iss. 16, 2005-01 ,pp. : 2295-2297

Adis International

Access to resources Recommend Favorite

Which drug combination for hormone-refractory prostate cancer?

By Doggrell Sheila A  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 4, 2005-04 ,pp. : 667-670

Informa Healthcare

Access to resources Recommend Favorite

Cabazitaxel: A Novel Drug for Hormone-Refractory Prostate Cancer

By  

Mini Reviews in Medicinal Chemistry, Vol. 13, Iss. 6, 2013-05 ,pp. : 915-920

Bentham Science Publishers

Access to resources Recommend Favorite

Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer

By Hoppe Bradford S.   Michalski Jeff M.   Mendenhall Nancy P.   Morris Christopher G.   Henderson Randal H.   Nichols Romaine C.   Mendenhall William M.   Williams Christopher R.   Regan Meredith M.   Chipman Jonathan J.   Crociani Catrina M.   Sandler Howard M.   Sanda Martin G.   Hamstra Daniel A.  

Cancer, Vol. 120, Iss. 7, 2014-04 ,pp. : 1076-1082

Blackwell Publishing

Access to resources Recommend Favorite